Merck Total Change in Assets/Liabilities 2010-2025 | MRK
Merck annual/quarterly total change in assets/liabilities history and growth rate from 2010 to 2025. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
- Merck total change in assets/liabilities for the quarter ending June 30, 2025 was $-5.971B, a 35.89% increase year-over-year.
- Merck total change in assets/liabilities for the twelve months ending June 30, 2025 was $-15.162B, a 22.97% increase year-over-year.
- Merck annual total change in assets/liabilities for 2024 was $-3.667B, a 66.3% increase from 2023.
- Merck annual total change in assets/liabilities for 2023 was $-2.205B, a 20.74% decline from 2022.
- Merck annual total change in assets/liabilities for 2022 was $-2.782B, a 27.53% decline from 2021.
Merck Annual Total Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$-3,667 |
| 2023 |
$-2,205 |
| 2022 |
$-2,782 |
| 2021 |
$-3,839 |
| 2020 |
$-4,601 |
| 2019 |
$-2,077 |
| 2018 |
$-1,553 |
| 2017 |
$-5,017 |
| 2016 |
$-2,601 |
| 2015 |
$-268 |
| 2014 |
$1,824 |
| 2013 |
$-794 |
| 2012 |
$-4,136 |
| 2011 |
$-766 |
| 2010 |
$930 |
| 2009 |
$-2,703 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$213.086B |
$64.168B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
